Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.

Ramirez AD, Liu X, Menniti FS.

Neuroendocrinology. 2003 Apr;77(4):223-31.

PMID:
12766322
2.

Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.

Callier S, Morissette M, Grandbois M, PĂ©laprat D, Di Paolo T.

Synapse. 2001 Aug;41(2):131-8.

PMID:
11400179
3.

Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.

Al-Sweidi S, Morissette M, Bourque M, Di Paolo T.

Neuropharmacology. 2011 Sep;61(4):583-91. doi: 10.1016/j.neuropharm.2011.04.031. Epub 2011 May 11.

PMID:
21586296
4.

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice.

Grandbois M, Morissette M, Callier S, Di Paolo T.

Neuroreport. 2000 Feb 7;11(2):343-6.

PMID:
10674483
5.

Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.

D'Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T.

Synapse. 2003 Jan;47(1):10-4.

PMID:
12422368
6.
7.
8.

Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.

Al-Sweidi S, Morissette M, Di Paolo T.

J Neuroendocrinol. 2012 Nov;24(11):1375-85. doi: 10.1111/j.1365-2826.2012.02349.x.

PMID:
22672467
9.

Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.

Bourque M, Dluzen DE, Di Paolo T.

Front Neuroendocrinol. 2012 Apr;33(2):169-78. doi: 10.1016/j.yfrne.2012.02.003. Epub 2012 Mar 1. Review.

PMID:
22387674
10.
11.

Neuroprotection in Parkinson models varies with toxin administration protocol.

Anderson DW, Bradbury KA, Schneider JS.

Eur J Neurosci. 2006 Dec;24(11):3174-82.

PMID:
17156378
13.

Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

Araki T, Muramatsu Y, Tanaka K, Matsubara M, Imai Y.

Neurosci Lett. 2001 Oct 12;312(1):50-4.

PMID:
11578843
14.

Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA.

J Neurosci. 2006 Jan 11;26(2):535-41.

15.
16.
17.

Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.

Liu LX, Chen WF, Xie JX, Wong MS.

Neurosci Res. 2008 Feb;60(2):156-61. Epub 2007 Oct 23.

PMID:
18054104
18.

Neuroprotective effects of Bak Foong Pill in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-induced Parkinson's disease model mice.

Liu B, Xie JX, Rowlands DK, Gou YL, Leung CC, Chung YW, Chan HC.

Biol Pharm Bull. 2004 Aug;27(8):1245-50.

19.

Neuroprotective effect of riluzole in MPTP-treated mice.

Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y.

Brain Res. 2001 Nov 9;918(1-2):176-81.

PMID:
11684056
20.

Minocycline enhances MPTP toxicity to dopaminergic neurons.

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS.

J Neurosci Res. 2003 Oct 15;74(2):278-85.

PMID:
14515357

Supplemental Content

Support Center